EV71疫苗与乙肝疫苗及A群流脑多糖疫苗同时接种的免疫原性与安全性:4期随机非劣效试验
该4期开放标签随机非劣效试验纳入775名6月龄健康婴儿,比较EV71疫苗第1剂与乙肝疫苗第1天同时接种、第2剂与A群流脑多糖疫苗第30天同时接种,与各疫苗单独接种的免疫原性和安全性。结果显示同时接种组对三种病原的血清阳转率非劣效于单独接种组,不良反应发生率组间相当。
要点
- 6月龄婴儿同时接种EV71疫苗、乙肝疫苗和A群流脑多糖疫苗的免疫应答非劣效于单独接种。
- 同时接种组与单独接种组的不良反应发生率相当,安全性可接受。
- 该方案为婴儿期多种疫苗同时接种提供了证据支持。
核心结论
- EV71疫苗与乙肝疫苗及A群流脑多糖疫苗同时接种的免疫原性和安全性非劣效于各疫苗单独接种。
研究设计与样本
- 4期、开放标签、单中心、随机、非劣效试验,共纳入775名6月龄健康婴儿,按1:1:1随机分为三组。
- SI组第1天同时接种EV71疫苗第1剂和乙肝疫苗、第30天同时接种EV71疫苗第2剂和A群流脑多糖疫苗;SE1组仅第1天和第30天分别接种EV71疫苗第1、2剂;SE2组仅第1天和第30天分别接种乙肝疫苗和A群流脑多糖疫苗。
主要发现
- 符合方案集分析显示,无论接种安排如何,针对EV71、乙肝病毒和A群流脑多糖的抗体应答相似。
- 非劣效界值设为10%时,SI组三种病原的血清阳转率分别为100%[98.25, 100]、44.84%[38.20, 51.63]和27.83%[21.91, 34.38],非劣效于SE1或SE2组的100%[98.31, 100]、44.35%[37.82, 51.02]和29.17%[23.20, 35.72]。
- 各接种方案的不良反应频率相当:SI组60.62%,SE1组52.33%,SE2组56.98%(P = .16)。
关键数值与推荐
- 非劣效界值设定为10%。
- SI组EV71血清阳转率100%[98.25, 100],乙肝44.84%[38.20, 51.63],A群流脑多糖27.83%[21.91, 34.38]。
- SE1或SE2组EV71血清阳转率100%[98.31, 100],乙肝44.35%[37.82, 51.02],A群流脑多糖29.17%[23.20, 35.72]。
- 不良反应发生率SI组60.62%、SE1组52.33%、SE2组56.98%,P = .16。
临床怎么用
- 6月龄婴儿可考虑将EV71疫苗与乙肝疫苗及A群流脑多糖疫苗按程序同时接种,免疫原性和安全性非劣效于单独接种。
局限性
- 本研究为开放标签、单中心设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study tested the hypothesis that the immunogenicity and safety of the simultaneous administration of enterovirus 71 (EV71) vaccine (dose 1) with recombinant hepatitis B vaccine (HepB) on day 1 and EV71 vaccine (dose 2) with group A meningococcal polysaccharide vaccine (MenA) on day 30 is not inferior to separate administration of each vaccine. METHODS: The study was designed as a randomized, open-label, noninferiority trial. A total of 775 healthy infants aged 6 months were randomly assigned in a ratio of 1:1:1 to receive simultaneous administration of EV71 vaccine (dose 1) and HepB on day 1 and EV71 vaccine (dose 2) and MenA on day 30 (the SI group); administration of doses 1 and 2 of EV71 vaccine on days 1 and 30, respectively (the SE1 group); or administration of HepB and MenA on days 1 and 30, respectively (the SE2 group). RESULTS: According to the per protocol set, antibody responses against EV71, hepatitis B virus (HBV), and group A meningococcal polysaccharide were similar regardless of administration schedule. With the non-inferiority margin setting at 10%, the seroconversion rates of the three pathogens in the SI group (100% [98.25, 100], 44.84% [38.20, 51.63] and 27.83% [21.91, 34.38]) were not inferior to those in SE1 or SE2 group (100% [98.31, 100], 44.35% [37.82, 51.02] and 29.17% [23.20, 35.72], respectively). Frequencies of adverse reactions to each vaccination regimen were comparable (60.62% in the SI group vs 52.33% in the SE1 group and 56.98% in the SE2 group; P = .16). CONCLUSIONS: Simultaneous administration of combined EV71 vaccine with HepB and MenA has noninferior immunogenicity and safety, compared with separate administration of these vaccines. CLINICAL TRIALS REGISTRATION: NCT03274102.
引用
- Zhang Z, Liang Z, Zeng J, et al. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial. J Infect Dis. 2019. PMID: 30891604. doi:10.1093/infdis/jiz129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。